GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CureVac NV (WBO:CVAC) » Definitions » Cash Flow from Financing

CureVac NV (WBO:CVAC) Cash Flow from Financing : €-4.94 Mil (TTM As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is CureVac NV Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Mar. 2024, CureVac NV paid €0.00 Mil more to buy back shares than it received from issuing new shares. It spent €1.22 Mil paying down its debt. It paid €0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received €0.00 Mil from paying cash dividends to shareholders. It received €0.10 Mil on other financial activities. In all, CureVac NV spent €1.12 Mil on financial activities for the three months ended in Mar. 2024.


CureVac NV Cash Flow from Financing Historical Data

The historical data trend for CureVac NV's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CureVac NV Cash Flow from Financing Chart

CureVac NV Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Financing
Get a 7-Day Free Trial 67.98 819.83 344.96 63.17 230.89

CureVac NV Quarterly Data
Mar19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 234.71 -1.20 -1.21 -1.41 -1.12

CureVac NV Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

CureVac NV's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:

CureVac NV's Cash from Financing for the quarter that ended in Mar. 2024 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-4.94 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CureVac NV  (WBO:CVAC) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

CureVac NV's issuance of stock for the three months ended in Mar. 2024 was €0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

CureVac NV's repurchase of stock for the three months ended in Mar. 2024 was €0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

CureVac NV's net issuance of debt for the three months ended in Mar. 2024 was €-1.22 Mil. CureVac NV spent €1.22 Mil paying down its debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

CureVac NV's net issuance of preferred for the three months ended in Mar. 2024 was €0.00 Mil. CureVac NV paid €0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

CureVac NV's cash flow for dividends for the three months ended in Mar. 2024 was €0.00 Mil. CureVac NV received €0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

CureVac NV's other financing for the three months ended in Mar. 2024 was €0.10 Mil. CureVac NV received €0.10 Mil on other financial activities.


CureVac NV Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of CureVac NV's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


CureVac NV (WBO:CVAC) Business Description

Industry
Traded in Other Exchanges
Address
Friedrich-Miescher-Strasse 15, Tubingen, BW, DEU, 72076
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.